227 related articles for article (PubMed ID: 30717807)
1. Transcriptomic expression profiling identifies ITGBL1, an epithelial to mesenchymal transition (EMT)-associated gene, is a promising recurrence prediction biomarker in colorectal cancer.
Matsuyama T; Ishikawa T; Takahashi N; Yamada Y; Yasuno M; Kawano T; Uetake H; Goel A
Mol Cancer; 2019 Feb; 18(1):19. PubMed ID: 30717807
[TBL] [Abstract][Full Text] [Related]
2. ITGBL1 promotes migration, invasion and predicts a poor prognosis in colorectal cancer.
Qiu X; Feng JR; Qiu J; Liu L; Xie Y; Zhang YP; Liu J; Zhao Q
Biomed Pharmacother; 2018 Aug; 104():172-180. PubMed ID: 29772438
[TBL] [Abstract][Full Text] [Related]
3. A novel mesenchymal-associated transcriptomic signature for risk-stratification and therapeutic response prediction in colorectal cancer.
Matsuyama T; Kandimalla R; Ishikawa T; Takahashi N; Yamada Y; Yasuno M; Kinugasa Y; Hansen TF; Fakih M; Uetake H; Győrffy B; Goel A
Int J Cancer; 2020 Dec; 147(11):3250-3261. PubMed ID: 32657428
[TBL] [Abstract][Full Text] [Related]
4. Genome-wide Discovery and Identification of a Novel miRNA Signature for Recurrence Prediction in Stage II and III Colorectal Cancer.
Kandimalla R; Gao F; Matsuyama T; Ishikawa T; Uetake H; Takahashi N; Yamada Y; Becerra C; Kopetz S; Wang X; Goel A
Clin Cancer Res; 2018 Aug; 24(16):3867-3877. PubMed ID: 29514841
[No Abstract] [Full Text] [Related]
5. An immune, stroma, and epithelial-mesenchymal transition-related signature for predicting recurrence and chemotherapy benefit in stage II-III colorectal cancer.
Cai D; Wang W; Zhong ME; Fan D; Liu X; Li CH; Huang ZP; Zhu Q; Lv MY; Hu C; Duan X; Wu XJ; Gao F
Cancer Med; 2023 Apr; 12(7):8924-8936. PubMed ID: 36629124
[TBL] [Abstract][Full Text] [Related]
6. MiR-139-5p as a novel serum biomarker for recurrence and metastasis in colorectal cancer.
Miyoshi J; Toden S; Yoshida K; Toiyama Y; Alberts SR; Kusunoki M; Sinicrope FA; Goel A
Sci Rep; 2017 Mar; 7():43393. PubMed ID: 28262692
[TBL] [Abstract][Full Text] [Related]
7. KRT17 as a prognostic biomarker for stage II colorectal cancer.
Ujiie D; Okayama H; Saito K; Ashizawa M; Thar Min AK; Endo E; Kase K; Yamada L; Kikuchi T; Hanayama H; Fujita S; Sakamoto W; Endo H; Saito M; Mimura K; Saze Z; Momma T; Ohki S; Kono K
Carcinogenesis; 2020 Jul; 41(5):591-599. PubMed ID: 31754689
[TBL] [Abstract][Full Text] [Related]
8. A Composite Gene Expression Signature Optimizes Prediction of Colorectal Cancer Metastasis and Outcome.
Schell MJ; Yang M; Missiaglia E; Delorenzi M; Soneson C; Yue B; Nebozhyn MV; Loboda A; Bloom G; Yeatman TJ
Clin Cancer Res; 2016 Feb; 22(3):734-45. PubMed ID: 26446941
[TBL] [Abstract][Full Text] [Related]
9. ColoGuideEx: a robust gene classifier specific for stage II colorectal cancer prognosis.
Agesen TH; Sveen A; Merok MA; Lind GE; Nesbakken A; Skotheim RI; Lothe RA
Gut; 2012 Nov; 61(11):1560-7. PubMed ID: 22213796
[TBL] [Abstract][Full Text] [Related]
10. An Individualized EMT-Related Gene Signature to Predict Recurrence-Free Survival in Stage II/III Colorectal Cancer Patients.
Zhang W; Zhang X; Zhao D; Hu M; Ge X; Xia L
Dig Dis Sci; 2022 Nov; 67(11):5116-5126. PubMed ID: 35094253
[TBL] [Abstract][Full Text] [Related]
11. A molecular signature for the prediction of recurrence in colorectal cancer.
Wang L; Shen X; Wang Z; Xiao X; Wei P; Wang Q; Ren F; Wang Y; Liu Z; Sheng W; Huang W; Zhou X; Du X
Mol Cancer; 2015 Feb; 14(1):22. PubMed ID: 25645394
[TBL] [Abstract][Full Text] [Related]
12. A comprehensive analysis of potential gastric cancer prognostic biomarker ITGBL1 associated with immune infiltration and epithelial-mesenchymal transition.
Wang Z; Fu L; Zhang J; Ge Y; Guo C; Wang R; Deng M; Wang Q; Wang Z
Biomed Eng Online; 2022 May; 21(1):30. PubMed ID: 35596183
[TBL] [Abstract][Full Text] [Related]
13. Recurrence-associated gene signature optimizes recurrence-free survival prediction of colorectal cancer.
Tian X; Zhu X; Yan T; Yu C; Shen C; Hu Y; Hong J; Chen H; Fang JY
Mol Oncol; 2017 Nov; 11(11):1544-1560. PubMed ID: 28796930
[TBL] [Abstract][Full Text] [Related]
14. Integrated analysis identifies an immune-based prognostic signature for the mesenchymal identity in colorectal cancer.
Zhang B; Wang L; Liu Z; Shao B; Jiang W; Shu P
Medicine (Baltimore); 2020 Jun; 99(25):e20617. PubMed ID: 32569190
[TBL] [Abstract][Full Text] [Related]
15. IBSP, a potential recurrence biomarker, promotes the progression of colorectal cancer via Fyn/β-catenin signaling pathway.
Chen Y; Qin Y; Dai M; Liu L; Ni Y; Sun Q; Li L; Zhou Y; Qiu C; Jiang Y
Cancer Med; 2021 Jun; 10(12):4030-4045. PubMed ID: 33987980
[TBL] [Abstract][Full Text] [Related]
16. A network-based predictive gene expression signature for recurrence risks in stage II colorectal cancer.
Yang WJ; Wang HB; Wang WD; Bai PY; Lu HX; Sun CH; Liu ZS; Guan DK; Yang GW; Zhang GL
Cancer Med; 2020 Jan; 9(1):179-193. PubMed ID: 31724326
[TBL] [Abstract][Full Text] [Related]
17. A prognostic mutation panel for predicting cancer recurrence in stages II and III colorectal cancer.
Sho S; Court CM; Winograd P; Russell MM; Tomlinson JS
J Surg Oncol; 2017 Dec; 116(8):996-1004. PubMed ID: 28767131
[TBL] [Abstract][Full Text] [Related]
18. Assessment of Nuclear ZEB2 as a Biomarker for Colorectal Cancer Outcome and TNM Risk Stratification.
Sreekumar R; Harris S; Moutasim K; DeMateos R; Patel A; Emo K; White S; Yagci T; Tulchinsky E; Thomas G; Primrose JN; Sayan AE; Mirnezami AH
JAMA Netw Open; 2018 Oct; 1(6):e183115. PubMed ID: 30646224
[TBL] [Abstract][Full Text] [Related]
19. A prognostic index based on an eleven gene signature to predict systemic recurrences in colorectal cancer.
Kim SK; Kim SY; Kim CW; Roh SA; Ha YJ; Lee JL; Heo H; Cho DH; Lee JS; Kim YS; Kim JC
Exp Mol Med; 2019 Oct; 51(10):1-12. PubMed ID: 31578316
[TBL] [Abstract][Full Text] [Related]
20. Large-Scale Analysis of Gene Expression Data Reveals a Novel Gene Expression Signature Associated with Colorectal Cancer Distant Recurrence.
Alajez NM
PLoS One; 2016; 11(12):e0167455. PubMed ID: 27935967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
